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Abstract
Background: Primary care physicians (PCPs) typically manage early chronic kidney disease (CKD), but recent
guidelines recommend nephrology co-management for some patients with stage 3 CKD and all patients with
stage 4 CKD. We sought to compare quality of care for co-managed patients to solo managed patients.
Methods: We conducted a retrospective cross-sectional analysis. Patients included in the study were adults who visited
a PCP during 2009 with laboratory evidence of CKD in the preceding two years, defined as two estimated glomerular
filtration rates (eGFR) between 15–59 mL/min/1.73 m2 separated by 90 days. We assessed process measures (serum eGFR
test, urine protein/albumin test, angiotensin converting enzyme inhibitor or angiotensin receptor blocker [ACE/ARB]
prescription, and several tests monitoring for complications) and intermediate clinical outcomes (mean blood pressure
and blood pressure control) and performed subgroup analyses by CKD stage.
Results: Of 3118 patients, 11 % were co-managed by a nephrologist. Co-management was associated with younger age
(69 vs. 74 years), male gender (46 % vs. 34 %), minority race/ethnicity (black 32 % vs. 22 %; Hispanic 13 % vs. 8 %),
hypertension (75 % vs. 66 %), diabetes (42 % vs. 26 %), and more PCP visits (5.0 vs. 3.9; p< 0.001 for all comparisons). After
adjustment, co-management was associated with serum eGFR test (98 % vs. 94 %, p=<0.0001), urine protein/albumin test
(82 % vs 36 %, p< 0.0001), and ACE/ARB prescription (77 % vs. 69 %, p= 0.03). Co-management was associated with
monitoring for anemia and metabolic bone disease, but was not associated with lipid monitoring, differences in mean
blood pressure (133/69 mmHg vs. 131/70 mmHg, p> 0.50) or blood pressure control. A subgroup analysis of Stage 4 CKD
patients did not show a significant association between co-management and ACE/ARB prescription (80 % vs. 73 %, p= 0.26).
Conclusion: For stage 3 and 4 CKD patients, nephrology co-management was associated with increased stage-appropriate
monitoring and ACE/ARB prescribing, but not improved blood pressure control.
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Background
Twenty-six million Americans have chronic kidney disease
(CKD). Approximately 90 % of CKD patients are in an early
stage of the disease and are typically cared for by primary
care physicians (PCPs). U.S. and international guidelines
recommend that physicians monitor for progression,
monitor for complications, prescribe medications to delay
progression, and focus on cardiovascular risk modification,
all of which are within a PCP’s scope of practice [1]. Recent
international guidelines, however, recommend nephrology
co-management for some patients with stage 3 CKD and
all patients with stage 4 CKD, based on the assumption that
co-management lessens complications, delays renal failure,
and decreases mortality [2]. While nephrologist involve-
ment is associated with decreased mortality for the small
group of patients who progress to end stage renal disease
and need renal replacement therapy [3, 4], we do not know
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whether co-management of a larger proportion of stage 3
patients and all stage 4 patients will improve quality of care.
To assess the relationship between nephrology co-manage-
ment and quality of care, we conducted a retrospective
cross-sectional analysis of electronic health record (EHR)
data for patients with stage 3 and 4 CKD, comparing co-
managed patients to solo managed patients.
Methods
Study population and setting
After receiving approval from the Partners Healthcare Hu-
man Research Committee and being granted waiver of
consent, we electronically screened all patients who had at
least one visit to a PCP at one of 12 primary care clinics in
the Brigham and Women’s Primary Care Practice Based
Research Network during 2009. This network includes
hospital-based and community-based clinics, two of which
are federally qualified health centers. We included adult
patients with stage 3 or 4 CKD, defined as two past esti-
mated glomerular filtration rates (eGFR) between
15–60 mL/min/1.73 m2, separated by 90 days and col-
lected during routine clinical care between January 1,
2007 to December 31, 2008 [5]. This approach allowed us
to identify a cohort of patients who had CKD at the
beginning of calendar year 2009. We excluded patients
with documented end-stage renal disease.
Data source
Data sources were billing data and EHR data. The practices
have used the home-grown, CCHIT-certified, Longitudinal
Medical Record EHR since July 2000. We used billing data,
rather than EHR data, to identify clinic visits because the
EHR notes do not specify whether nephrologist consulta-
tions were inpatient or outpatient. For the outcomes, we
used EHR data. We queried the EHR for laboratory results,
medications, and blood pressure measurements from 2009.
PCPs prescribed all medications through the EHR and
medications which were not prescribed by PCPs were in-
cluded on the medication list as well. All outpatient vital
signs were recorded in the EHR. Covariates such as socio-
demographic data were collected during registration and
updated periodically in the EHR. Our data was collected in
2009 because a large-scale EHR intervention was imple-
mented in 2010 to increase recognition of CKD [6].
Exposure, outcomes, and covariates
We defined the exposure, nephrology co-management, as
at least one outpatient visit with a nephrologist over the
course of the year 2009 according to billing data. The
quality of care outcomes were derived from nationally
accepted guidelines [5, 7]. We examined the following
outcomes: 1) annual serum eGFR test (a measurement
during the year 2009, in addition to the two measure-
ments over 2007–2008 that were used for inclusion), 2)
annual urine albumin/protein test, 3) an angiotensin con-
verting enzyme inhibitor or angiotensin receptor blocker
(ACE/ARB) prescription, 4) annual LDL test, 5) annual
serum hemoglobin/hematocrit test, 6) annual serum cal-
cium test, 7) annual serum phosphorus test, 8) annual
serum parathyroid test for patients with stage 4 CKD, 9)
mean blood pressure (BP; using last value for SBP and last
value for DBP), and 10) BP control.
For the urine protein monitoring outcome, we included
several tests: urine total protein, microalbumin, and
albumin-to-creatinine ratio. We used medication list data
to determine whether an ACE/ARB was listed as an active
medication during 2009. We used the most recent
recorded BP for BP outcomes. We examined hypertension
by assessing mean BP and BP control according to two
definitions: blood pressure ≤ 130/80 mmHg and ≤ 140/
90 mmHg, due to differing opinions about the appropriate
target for non-diabetic kidney disease in the absence of
proteinuria [7–10].
We stratified CKD patients into stage 3 (two measure-
ments of eGFR 30–59 mL/min/1.73 m2) and stage 4 (two
measurements of eGFR 16–29 mL/min/1.73 m2). We ex-
amined tests to monitor for complications of CKD differ-
ently for stage 3 and stage 4 patients [11–14]. For stage 3
patients we examined 1) annual serum hemoglobin test, 2)
annual serum calcium test and 3) annual serum phos-
phorus test. For stage 4 patients, we additionally examined
annual serum parathyroid hormone test.
We examined several potential confounders of the rela-
tionship between co-management and outcomes by first
assessing association between the potential confounder
and co-management. We examined socio-demographic
variables (age, gender and race), severity of disease as
measured by eGFR, and co-morbid diabetes and hyperten-
sion, and the frequency of PCP visits. We hypothesized
that PCP diagnosis of CKD could be related to, or on the
causal pathway to, referral and so we examined the impact
of adjusting for this variable in fully adjusted models.
Statistical analysis
We examined the association of nephrology co-
management and outcomes for stage 3 and stage 4
CKD patients and then performed subgroup analyses
stratified by CKD stage.
We first analyzed the data assuming that the out-
come was independent and then repeated the analyses
accounting for clustering by PCP. Since we found
similar results, we present all results accounting for
clustering by PCP. We used multivariable logistic and
linear regression to adjust for potential confounders
and to produce weighted estimates (weighted to ad-
just for covariates and to account for clustering using
the LSMEANS feature of the GENMOD procedure in
SAS, SAS Institute, Cary, NC).
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Results and discussion
Patient characteristics
Of the 79,605 patients who made a visit to a PCP in
2009, we identified 3,118 patients (4 %) with stage 3
or 4 CKD. Patients had a mean age of 74 years and
were predominantly female (Table 1). Race/ethnicity
rates were 67 % White, 23 % Black, 8 % Hispanic,
and 1.5 % Asian. The average eGFR was 46 mL/min/
1.73 m2, 27 % had diabetes, 67 % had hypertension,
and, on average, patients saw their PCP 4 times dur-
ing the year.
Nephrology co-management
Of the 3,118 stage 3 and 4 CKD patients, 341 (11 %) had at
least one visit with a nephrologist during 2009 [191 (7.5 %)
of stage 3 patients and 94 (50 %) of stage 4 patients]. On
average, patients saw nephrology twice during the year
(Table 1). Nephrology co-management was associated with
younger age, male gender, Black or Hispanic race/ethnicity,
hypertension, diabetes, and more frequent PCP visits
(Table 1). Within the stage 4 CKD subgroup, the only
covariates associated with nephrology co-management were
younger age and more frequent PCP visits.
Outcome measures
Patients co-managed with nephrology were more likely
to have received tests monitoring for progression: serum
eGFR and urine protein/albumin (Table 2). We found
no evidence that PCP diagnosis of early CKD was
responsible for these differences.
Patients who were co-managed were more likely to
receive an ACE/ARB prescription (Table 2). The mean
BP was 133/72 mmHg. There were no significant associ-
ations between nephrology co-management and mean
BP before or after adjustment (Table 2). With a BP goal
of 140/90 mmHg, 71 % were under control and the like-
lihood of being under control was not associated with
nephrology co-management. With a BP goal of 130/








Age, mean (SD) 74 (12) 69 (13) 74 (12) P <0.0001
Male gender, N (%) 1108 (36 %) 155 (46 %) 953 (34 %) P <0.0001
Race/Ethnicity, N (%) P <0.0001
White 2060 (67 %) 177 (53 %) 1883 (69 %)
Black 716 (23 %) 108 (32 %) 608 (22 %)
Hispanic 253 (8 %) 45 (13 %) 208 (8 %)
Asian 46 (2 %) 7 (2 %) 39 (1 %)
Serum Creatinine, mean (SD) 1.46 (0.8) 2.28 (1.3) 1.36 (0.6) P <0.0001
eGFR (average of 2 values), mean (SD) 46.0 (9.89) 35.6 (11.1) 47.3 (8.92) P <0.0001
CKD Stage, N (%) (based on average of 2 values)
3a (eGFR 45–59 mL/min/1.73 m2) 1929 (62 %) 80 (23 %) 1849 (67 %)
3b (eGFR 30–44 mL/min/1.73 m2) 926 (30 %) 144 (42 %) 782 (28 %)
4 (eGFR 15–29 mL/min/1.73 m2) 255 (8 %) 117 (34 %) 138 (5 %)
Serum Hematocrit, mean (SD) 37.2 (4.6) 35.6 (4.9) 37.4 (4.6) P <0.0001
Diabetes on problem list, N (%) 851 (27 %) 143 (42 %) 708 (26 %) P <0.0001
Hypertension on problem list, N (%) 2099 (67 %) 254 (75 %) 1845 (66 %) P = 0.003
Tobacco Use, N (%) P = 0.02
Current 179 (8 %) 33 (12 %) 146 (7 %)
Former 960 (41 %) 107 (38 %) 853 (41 %)
Never 1224 (52 %) 143 (51 %) 1081 (52 %)
Insurance status, N (%) P = 0.002
Public 2391 (77 %) 252 (74 %) 2139 (77 %)
Private 620 (20 %) 66 (19 %) 554 (20 %)
Self Pay 107 (4 %) 23 (7 %) 84 (3 %)
PCP visits yearly, mean (SD) 4.0 (2.9) 5.0 (3.6) 3.9 (2.8) P <0.0001
Nephrology visits yearly, mean (SD) N/A 2.3 (1.5) N/A N/A
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80 mmHg, 45 % were under control and the likelihood
of BP being under control was not associated with neph-
rology co-management.
In stage 3 patients, nephrology co-management was
associated with tests monitoring for progression (serum
eGFR and urine protein/albumin), tests monitoring for
complications (serum hemoglobin, serum calcium, and
serum phosphorus), both before and after adjustment
for potential confounders (Table 3). Co-management
was associated with serum LDL testing before adjust-
ment only. Patients who were co-managed were more
likely to receive an ACE/ARB prescription. There were
no differences in BP outcomes.
In stage 4 patients, nephrology co-management was
associated with a higher rate of one test monitoring for
progression (urine protein/albumin), and tests monitoring
for complications (serum hemoglobin, serum phosphorus,
and serum parathyroid hormone), both before and after
adjustment for potential confounders (Table 4). Co-
management was associated with serum calcium testing
before adjustment only (p = 0.04). Co-management was
associated with mean diastolic blood pressure after
Table 2 Association of nephrology co-management with quality of care for pooled stage 3 and stage 4 CKD patients







Solo PCP management p value
Serum eGFRc 100 % 93 % P < 0.0001 98 % 94 % P < 0.0001
Urine protein 87 % 37 % P <0.0001 82 % 36 % P < 0.0001
ACE/ARB prescription 81 % 65 % P < 0.0001 77 % 69 % P = 0.03
BP <140/90 68 % 72 % P = 0.15 70 % 73 % P = 0.41
BP <130/80 47 % 45 % P = 0.40 47 % 46 % P = 0.68
Mean Mean Weighted estimate Weighted estimate
Systolic, mmHg 133.1 132.4 P = 0.54 132.6 130.8 P = 0.15
Diastolic, mmHg 70.9 72.1 P = 0.13 69.0 70.2 P = 0.12
aAll estimates account for clustering by PCP
bWeighted percentage and p value estimated by multivariate model accounting for clustering by PCP and adjusting for age, gender, race/ethnicity, eGFR,
hypertension, diabetes, and number of PCP visits
cLinear model due to 100 % rate in co-management group
Table 3 Association of nephrology co-management with quality of care measures for CKD patients, stage 3 only










Serum eGFRc 100 % 93 % P < 0.0001 98 % 94 % P < 0.0001
Urine protein 88 % 36 % P < 0.0001 85 % 34 % P < 0.0001
ACE/ARB prescription 84 % 65 % P < 0.0001 79 % 69 % P = 0.02
BP <140/90 mmHg 71 % 71 % P = 0.93 71 % 72 % P = 0.68
BP <130/80 mmHg 48 % 45 % P = 0.36 46 % 45 % P = 0.96
Serum LDL 83 % 77 % P = 0.02 79 % 78 % P = 0.74
Serum Hemoglobin or
Hematocrit
96 % 79 % P < 0.0001 96 % 83 % P < 0.0001
Serum Calcium 99 % 91 % P < 0.0001 99 % 93 % P = 0.0002
Serum Phosphorus 81 % 18 % P < 0.0001 76 % 17 % P < 0.0001
Mean Mean Weighted estimate Weighted estimate
Systolic, mmHg 132.8 132.5 P = 0.81 133.8 132.1 P = 0.21
Diastolic, mmHg 72.7 72.1 P = 0.57 71.9 72.1 P = 0.84
aAll estimates account for clustering by PCP
bPercentage and p value estimated by multivariate model accounting for clustering by PCP and adjusting for age, gender, race/ethnicity, eGFR, hypertension,
diabetes, and number of PCP visits
cLinear model due to 100 % rate in co-management group
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adjustment only (p = 0.0007). Nephrology co-management
was not associated with ACE/ARB prescription, mean sys-
tolic blood pressure, or blood pressure control.
Discussion
We found that only a small proportion (8 %) of stage 3
CKD patients and half of stage 4 CKD patients were co-
managed by nephrology. Co-management was associated
with socio-demographic differences, particularly in stage 3
CKD patients for whom co-management was associated
with younger age, male gender and minority race/ethni-
city. Co-management was associated with diabetes, hyper-
tension, and more frequent PCP visits. After controlling
for these potential confounders, co-management was asso-
ciated with monitoring tests, both for progression and for
complications. Co-management was associated with higher
rates of ACE/ARB prescription in stage 3 CKD, but not in
stage 4 CKD. Co-management was not associated with
higher rates of cardiovascular risk modification through
lipid monitoring or blood pressure control.
Our finding of a difference between the two groups for
ACE/ARB prescription in stage 3, though not in stage 4,
is in concert with another recently published study from
the Chronic Renal Insuffiency Cohort (CRIC) [15]. One
explanation for the higher impact of nephrology co-
management in stage 3 CKD as compared to stage 4
CKD is low PCP recognition of CKD in stage 3. As we
showed in a prior study, PCPs are more likely to diag-
nose CKD in patients with more advanced disease [16].
Co-management was associated with age, gender, and
race/ethnicity. These associations align with patients
who have higher muscle mass. This may indicate PCPs
are still using serum creatinine levels rather than eGFR
to judge severity of CKD in early disease. The only
socio-demographic characteristic associated with neph-
rology referral in stage 4 CKD was younger age. PCPs
were more likely to refer patients with diabetes in the
stage 3 subgroup, which may reflect a higher rate of
urine albumin screening and appropriate subsequent
referral of albuminuric patients [16]. Patients who saw
their PCP less often were less likely to be referred, which
may reflect competing demands during office visits [17, 18].
We saw a similar dose–response relationship between
the number of primary care visits and CKD documenta-
tion in our prior study [16] and the AVENIR study
found a dose–response relationship between the num-
ber of nephrology visits and quality of care [19].
Other primary care CKD studies have revealed sub-
optimal urine protein testing, serum phosphorus testing,
serum parathyroid hormone testing, prescription of
ACE/ARB, and blood pressure control [16, 20–22]. The
AVENIR nephrology clinic study reported low rates,
similar to ours, of urine protein testing at 50 % and
ACE/ARB prescription at 67 %, in addition to a BP con-
trol rate of 14 % (<130/80 mmHg), lower than ours [19].
One U.S. study designed to examine the impact of auto-
mated eGFR reporting also compared co-managed and solo
managed patients (in stage 3b and 4, or eGFR 15–45 mL/
min/1.73 m2). They found a significant difference in serum
Table 4 Association of nephrology co-management with quality of care measures for CKD patients, stage 4 only










Serum eGFRc 100 % 97 % P = 0.08 100 % 97 % P = 0.09
Urine protein 86 % 60 % P < 0.0001 88 % 56 % P < 0.0001
ACE/ARB prescription 77 % 72 % P = 0.41 80 % 73 % P = 0.26
BP <140/90 mmHg 64 % 69 % P = 0.51 64 % 70 % P = 0.52
BP <130/80 mmHg 46 % 47 % P = 0.97 48 % 44 % p = 0.59
Serum LDL 76 % 73 % P = 0.59 77 % 80 % P = 0.69
Serum Hemoglobin or
Hematocritc
99 % 91 % P = 0.01 99 % 91 % P = 0.04
Serum Calciumc 100 % 96 % P = 0.04 100 % 96 % P = 0.05
Serum Phosphorus 90 % 49 % P < 0.0001 91 % 50 % P < 0.0001
Serum PTH 92 % 32 % P < 0.0001 92 % 33 % P < 0.0001
Mean Mean Weighted estimate Weighted estimate
Systolic, mmHg 132.3 131.7 P = 0.85 130.6 130.0 p = 0.84
Diastolic, mmHg 67.7 71.2 P = 0.06 64.6 69.9 P = 0.0007
aAll estimates account for clustering by PCP
bPercentage and p value estimated by multivariate model accounting for clustering by PCP and adjusting for age, gender, race/ethnicity, eGFR, hypertension,
diabetes, and number of PCP visits. Race/ethnicity categories were collapsed to White, Black, Other due to inability to perform logistic regression with small cells
cLinear model due to 100 % rate in co-management group
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hemoglobin testing, serum phosphorus testing, and
serum PTH testing, but neither urine protein testing
(with a rate of <30 % overall) nor ACE/ARB prescribing
(with a rate of <60 % overall) [23]. Ours is the first study
to examine blood pressure outcomes in a similar manner.
There are several limitations to this study. There is a
potential for type II error when we conclude that there
is no difference in BP control between groups because
co-managed patients may be sicker than solo managed
patients. An analysis of anti-hypertensive regimens
would help to elucidate any difference in management.
There may be other patient level confounders for which
we were unable to adjust. ACE/ARB prescriptions were
assessed in all CKD patients, though these are only rec-
ommended for patients with either hypertension, dia-
betic kidney disease, or proteinuria. Our laboratory uses
the MDRD equation to calculate eGFR without account-
ing for race. Generalizability is limited by the fact that
the population is limited to one primary care network.
We were unable to measure clinical outcomes such as
progression to ESRD and mortality.
Our findings have implications for the following: 1) PCP
solo management, 2) nephrology co-management, and de-
veloping a systematic approach to referral to nephrology.
First, PCPs should improve solo management in stage
3 CKD through monitoring for complications, monitor-
ing for progression of disease, and intervening to delay
progression. One successful approach is through point-
of-care EHR alerts that remind the physician of the diag-
nosis and recommended management of stage 3 CKD.
Such reminders have improved urine protein testing
[24]. A second approach which addresses the lack of
time in primary care visits is population management by
a non-physician. Nurse-led population management has
improved quality of care for diabetes and hypertension
[25, 26]. A study in one of our practices combined EHR
alerts and population management to successfully im-
prove PCP management of CKD [27].
Second, quality of care for co-managed patients could
improve as well. Co-management did not increase the
likelihood of cardiovascular risk modification in stage 3 or
stage 4 CKD. PCPs and nephrologists working together
should be able to control patients’ blood pressure, yet we
saw no difference in this measure between solo managed
and co-managed patients. Both EHR alerts and population
management are likely to be part of the answer [26, 28],
but to date, there have been no successful systems-level
interventions for uncontrolled blood pressure in a CKD
population. Ideally, we will develop EHR alerts that are so-
phisticated enough to track management over time and to
consider previous medication regimens and drug allergies
[29, 30]. Perhaps more importantly, we should routinely
employ effective patient-centered interventions to im-
prove medication adherence [31, 32].
Third, and just as critical as the first (i.e. improving PCP
solo management) and the second (i.e. improving co-
management), is developing a systematic approach to refer-
ral. The current approach relies on creatinine-based
estimates of kidney function that do not accurately predict
whether and when patients might progress [38, 39]; many
patients do not progress.
That being said, two studies showed a slowing of progres-
sion in stage 3 CKD when nephrologists monitored patients
electronically and gave advice to PCPs [40, 41]. At this
point, we only have two studies to answer the important
question of whether we can delay or prevent progression to
ESRD through comanagement in stage 3 CKD. Further
studies would be welcome. A potentially better approach
would take into account the fact that nephrology referral
has a mortality benefit when done 12 to 72 months before
initiating dialysis [33–37]. PCPs may be aided by risk esti-
mation models such as one validated by Tangri and col-
leagues that incorporates additional metabolic parameters
beyond serum creatinine in order to predict how likely a
patient is to progress to renal failure within a five years [42].
Such prediction models could encourage PCPs to increase
appropriate referrals to nephrology based on length of time
before renal replacement therapy is needed, rather than
stage-based referral.
Conclusions
In conclusion, early CKD is commonly managed in primary
care, but patients who are co-managed by nephrology re-
ceive better monitoring for progression and complications.
Improving the quality of PCP solo management will help to
close this gap. In addition, about one-quarter of early CKD
patients have uncontrolled blood pressure whether they
have been referred to a nephrologist or not. We should
study interventions to improve co-management of blood
pressure and to decrease cardiovascular events. These inter-
ventions should include population management, EHR
tools, and patient-centered interventions. Finally, we have
sophisticated tools to risk-stratify patients with CKD and
we must learn how best to employ these tools in primary
care practices to systematize referral of high-risk patients.
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